Pono (NYSE:PONO) has entered into a definitive agreement to acquire Benuvia, Inc., a drug developer focused on pharmaceutical cannabinoids, at an enterprise value of $440 million. The Arizona-based company owns an FDA approved cannabinoid drug SYNDROS (dronabinol oral solution CII), and synthetic cannabinoid manufacturing facilities in the U.S. The combined company is expected to trade
Read More
Pono Capital Corp (PONO) to Combine with Benuvia in $440M Deal
Date:
Latest Intelligence
